Heikki Lanckriet Acquires 3,000 Shares of 4basebio (LON:4BB) Stock

4basebio PLC (LON:4BB) insider Heikki Lanckriet purchased 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was bought at an average price of GBX 576 per share, for a total transaction of £17,280.

4basebio Stock Performance

LON 4BB traded down GBX 25 during trading hours on Wednesday, hitting GBX 565. 805 shares of the stock were exchanged, compared to its average volume of 1,444. 4basebio PLC has a 12-month low of GBX 520 and a 12-month high of GBX 1,220. The stock has a 50-day moving average of GBX 609.02 and a 200 day moving average of GBX 739.02. The company has a market cap of £87.49 million, a price-to-earnings ratio of -5.71 and a beta of 1.09. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.